168 related articles for article (PubMed ID: 21494621)
1. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
Cerchietti L; Damm-Welk C; Vater I; Klapper W; Harder L; Pott C; Yang SN; Reiter A; Siebert R; Melnick A; Woessmann W
PLoS One; 2011 Apr; 6(4):e18436. PubMed ID: 21494621
[TBL] [Abstract][Full Text] [Related]
2. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
3. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
[TBL] [Abstract][Full Text] [Related]
4. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
Gascoyne RD; Lamant L; Martin-Subero JI; Lestou VS; Harris NL; Müller-Hermelink HK; Seymour JF; Campbell LJ; Horsman DE; Auvigne I; Espinos E; Siebert R; Delsol G
Blood; 2003 Oct; 102(7):2568-73. PubMed ID: 12763927
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.
Takeuchi K; Soda M; Togashi Y; Ota Y; Sekiguchi Y; Hatano S; Asaka R; Noguchi M; Mano H
Haematologica; 2011 Mar; 96(3):464-7. PubMed ID: 21134980
[TBL] [Abstract][Full Text] [Related]
6. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
7. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
[TBL] [Abstract][Full Text] [Related]
9. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
11. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement.
McManus DT; Catherwood MA; Carey PD; Cuthbert RJ; Alexander HD
Hum Pathol; 2004 Oct; 35(10):1285-8. PubMed ID: 15492998
[TBL] [Abstract][Full Text] [Related]
12. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
13. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Chen Z; Sasaki T; Tan X; Carretero J; Shimamura T; Li D; Xu C; Wang Y; Adelmant GO; Capelletti M; Lee HJ; Rodig SJ; Borgman C; Park SI; Kim HR; Padera R; Marto JA; Gray NS; Kung AL; Shapiro GI; Jänne PA; Wong KK
Cancer Res; 2010 Dec; 70(23):9827-36. PubMed ID: 20952506
[TBL] [Abstract][Full Text] [Related]
15. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
16. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Chikatsu N; Kojima H; Suzukawa K; Shinagawa A; Nagasawa T; Ozawa H; Yamashita Y; Mori N
Mod Pathol; 2003 Aug; 16(8):828-32. PubMed ID: 12920229
[TBL] [Abstract][Full Text] [Related]
17. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
18. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
19. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.
De Paepe P; Baens M; van Krieken H; Verhasselt B; Stul M; Simons A; Poppe B; Laureys G; Brons P; Vandenberghe P; Speleman F; Praet M; De Wolf-Peeters C; Marynen P; Wlodarska I
Blood; 2003 Oct; 102(7):2638-41. PubMed ID: 12750159
[TBL] [Abstract][Full Text] [Related]
20. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
Touriol C; Greenland C; Lamant L; Pulford K; Bernard F; Rousset T; Mason DY; Delsol G
Blood; 2000 May; 95(10):3204-7. PubMed ID: 10807789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]